

1 **Cumulative live birth rates after one or more complete cycles of IVF: a**
2 **population-based study of linked cycle data from 178,898 women**

3 David J McLernon^{1,*}, Abha Maheshwari², Amanda J Lee³, Siladitya Bhattacharya⁴

4 ¹Division of Applied Health Sciences, Polwarth Building, University of Aberdeen, Aberdeen, AB25

5 2ZD, UK ²Division of Applied Health Sciences, Polwarth Building, University of Aberdeen, Aberdeen,

6 AB25 2ZD, UK ³Division of Applied Health Sciences, Polwarth Building, University of Aberdeen,

7 Aberdeen, AB25 2ZD, UK ⁴Division of Applied Health Sciences, Polwarth Building, University of

8 Aberdeen, Aberdeen, AB25 2ZD, UK

9

10

11

12 ***Correspondence address:** DJ McLernon, Medical Statistics Team, Division of Applied Health

13 Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, UK, AB25 2ZD. Email:

14 d.mclernon@abdn.ac.uk

15

16 **Running title:** Cumulative live birth rates following IVF

17

18

19

20 **Abstract**

21 **Study question:** What is the chance of a live birth following one or more linked complete cycles of
22 IVF (including ICSI)?

23 **Summary answer:** The chance of a live birth after three complete cycles of IVF was 42.3% for
24 treatment commencing from 1999 to 2007.

25 **What is known already:** IVF success has generally been reported on the basis of live birth rates after
26 a single episode of treatment resulting in the transfer of a fresh embryo. This fails to capture the
27 real chance of having a baby after a number of complete cycles – each involving the replacement of
28 fresh as well as frozen-thawed embryos.

29 **Study design, size and duration:**

30 Population based observational cohort study of 178,898 women between 1992 and 2007.

31 **Participants/materials, setting, methods:**

32 Participants included all women who commenced IVF treatment at a licenced clinic in the UK as
33 recorded in the Human Fertilisation and Embryology Authority national database. Exclusion criteria
34 included women whose treatment involved donor insemination, egg donation, surrogacy, and the
35 transfer of more than three embryos. Cumulative rates of live birth, term (>37 weeks) singleton live
36 birth, and multiple pregnancy were estimated for two time-periods, 1992-1998 and 1999-2007.

37 Conservative estimates assumed that women who did not return for IVF would not have the
38 outcome of interest while optimal estimates assumed that these women would have similar
39 outcome rates to those who continued IVF.

40 **Main results and the role of chance:**

41 A total of 71,551 women commenced IVF treatment during 1992–1998 and an additional 107,347
42 during 1999–2007. After the third complete IVF cycle (defined as three fresh IVF treatments -
43 including replacement of any surplus frozen-thawed embryos), the conservative CLBR in women who

44 commenced IVF during 1992-1998 was 30.8% increasing to 42.3% during 1999-2007. The optimal
45 CLBRs were 44.6% and 57.1% respectively. After eight complete cycles the optimal CLBR was 82.4%
46 in the latter time period. The conservative rate for multiple pregnancy per pregnant woman fell
47 from 31.9% during the earlier time period to 26.2% during the latter.

48 **Limitations and reason for caution:**

49 Linkage of all IVF treatments to individual women was conducted. However, it was not possible to
50 identify with certainty in all cases the episode of ovarian stimulation which generated some of the
51 frozen embryos. Cumulative live birth rates could not be calculated for women who started
52 treatment beyond 2007 as follow up data were incomplete in some of them. Following a change in
53 legislation in 2008, linked data were only made available for research in women who gave formal
54 consent for this purpose.

55 **Wider implications of the findings:**

56 Our results demonstrate, at a national level, the chances of livebirth in couples undergoing a number
57 of complete (fresh and frozen) IVF cycles. They reflect improvements in reproductive technology and
58 a more conservative embryo transfer policy. Although most couples in the UK still do not receive
59 three complete IVF cycles; assuming no barriers to continuation of IVF treatment, around 83% of
60 women receiving IVF would achieve a live birth by the eighth complete cycle, similar to the natural
61 live birth rate in a non-contraception practising population. Our results support the call from NICE to
62 develop consistent IVF policies based on three complete cycles.

63 **Study funding/competing interest(s):** This work was funded by a Chief Scientist Office Postdoctoral
64 Training Fellowship in Health Services Research and Health of the Public Research (Ref PDF/12/06).
65 The views expressed here are those of the authors and not necessarily those of the Chief Scientist
66 Office. SB reports grants from Chief Scientist Office Scotland during the conduct of the study. His
67 institution has received support from Pharmaceutical companies (for educational seminars) which is
68 not related to the submitted work. DJM, AM and AJL have no conflicts of interest to declare.

69 **Key words:** Cumulative live birth rate, IVF, live birth, multiple pregnancy, time.

70

71

72

73 **Introduction**

74 Globally, the estimated prevalence of infertility is around 9% (Boivin et al. 2007), whilst in the UK,
75 around one in six couples experience problems conceiving (Oakley et al. 2008). Most couples with
76 prolonged unresolved infertility eventually proceed to in vitro fertilisation (defined here as IVF or
77 ICSI) and the number of women treated in the United Kingdom (UK) has increased annually from
78 6184 in 1991 to 49636 in 2013 (Human Fertilisation and Embryology Authority 2008a, Human
79 Fertilisation and Embryology Authority 2012, Human Fertilisation and Embryology Authority 2013a).
80 Worldwide, by the end of 2013 over five million people were estimated to have been born as a
81 result of IVF (Adamson et al. 2012), with the UK accounting for over 4% of this total (Human
82 Fertilisation and Embryology Authority 2014).

83 IVF success has generally been calculated and reported on the basis of live birth rates per treatment
84 attempt involving either an intended fresh or frozen-thawed embryo replacement (Vrtacnik et al.
85 2014, Elizur et al. 2006, Ke et al. 2013, Sharma et al. 2002, Abuzeid et al. 2014).

86 The continued improvement in reproductive technology has seen an increase in the number of
87 frozen-thawed embryo transfers (De Mouzon et al. 2010) and their associated pregnancy rates
88 (Roque et al. 2013). This, combined with an emphasis on reducing multiple pregnancies and
89 increasing single embryo transfers (National Collaborating Centre for Women's and Children's Health
90 2013), means that outcomes per fresh embryo transfer are no longer meaningful to patients and
91 clinicians who want to know their chance of a live birth over an entire IVF programme (Maheshwari
92 et al. 2015). The most appropriate way of reporting this is to estimate the cumulative chances of
93 success per woman after a number of complete cycles, - defined as all fresh and frozen-thawed
94 embryo transfer attempts resulting from one episode of ovarian stimulation (Moragianni and
95 Penzias 2010). The complete cycle definition allows realisation of the total reproductive potential of
96 each single fresh cycle including the contribution of all subsequent frozen-thawed embryo transfers
97 derived from it (Jones et al. 1997, Stern et al. 2012). Cumulative live birth rates (CLBRs) following IVF

98 have been reported mainly at a sub-national level (Vrtacnik et al. 2014, Ke et al. 2013, Malizia et al.
99 2009, Elizur et al. 2006). Although they have been reported at the national level in the United States
100 (Stern et al. 2013, Luke et al, 2012) and Australia and New Zealand (Macaldowie et al. 2013) not all
101 the reports have been able to generate figures for cumulative live birth after several complete IVF
102 cycles. Until now, no studies have reported such rates for the UK (Johnson and Franklin 2013). Given
103 the national shift towards elective single embryo transfer and freezing of surplus embryos (National
104 Collaborating Centre for Women's and Children's Health 2013, The Multiple Births Foundation,
105 2015), CLBRs are increasingly proving to be the currency of IVF. As such, it is important to determine
106 what their values are for couples embarking on IVF, and how they have changed over time with
107 increasing uptake of embryo freezing. Additionally, since multiple pregnancy is associated with
108 increased maternal and perinatal morbidity and mortality (Mansour et al. 2014, Sunderam et al.
109 2014), it is useful to explore whether changes in practice have resulted in reducing cumulative
110 multiple pregnancy rates and increasing the numbers of healthy babies – i.e. rates of term singleton
111 live births (Min et al. 2004).

112 The Human Fertilisation and Embryology Authority (HFEA) has collected data on all licensed fertility
113 treatments in the UK since 1992. An anonymised HFEA database is freely available for research
114 purposes and has been utilised in several studies (Human Fertilisation and Embryology Authority
115 2013b, Sunkara et al. 2011, Nelson and Lawlor 2011, Bhattacharya et al. 2013,). However, as it only
116 contains data at the individual (fresh or frozen) IVF treatment level there is no way of linking one or
117 more complete IVF cycles to an individual woman in order to estimate CLBRs. However, a more
118 detailed version of the HFEA database is available for research purposes under strict conditions
119 which links all IVF treatments to complete cycles and to individual women (Williams et al 2013) and
120 allows estimation of cumulative live birth rates. A population-based cohort study was conducted to
121 investigate the cumulative live birth rate per woman following one or more linked complete cycles
122 of IVF. This was repeated for outcomes of term singleton live birth per woman and multiple
123 pregnancy per pregnant woman following IVF. We also aimed to explore whether the cumulative

124 live birth rate increased over time and the characteristics of women accessing IVF as well as their
125 patterns of treatment over time.

126

127 **Methods**

128 ***Database access***

129 Access to the detailed HFEA database was subject to approval from the North of Scotland Research
130 Ethics Committee, the Confidentiality Advisory Group, and the HFEA Register Research Panel.
131 Consent for IVF patient data to be used in research changed from 'presumed' to 'required' in
132 October 2009. Therefore, from October 2009, only details relating to those patients who provided
133 explicit consent for their data to be used in research were available.

134 Anonymised "per woman" data were transferred to the University of Aberdeen where they were
135 stored and analysed using the dedicated secure Data Safe Haven (DaSH) University of Aberdeen
136 server with access restricted to approved researchers.

137 ***Study population***

138 Records of all fresh and frozen-thawed IVF (including ICSI) treatments in women who embarked on
139 IVF in the UK between January 1992 and December 2011 were extracted. Since the treatment
140 information were linked to the individual we were able to identify and code complete cycles of IVF
141 for each woman by combining her fresh treatment with its associated frozen-thawed treatments (so
142 that the total reproductive potential could be determined). For clarity, our definition of a complete
143 cycle is all fresh and frozen-thawed embryo transfer attempts resulting from one episode of ovarian
144 stimulation (National Collaborating Centre for Women's and Children's Health 2013). The following
145 exclusion criteria were applied:

- 146 1. Women having any element of treatment involving donor insemination, egg donation, and
147 surrogacy.
- 148 2. Women who had treatment where the express purpose was storage of eggs or embryos.
- 149 3. Women aged less than 18 or over 50 in their first treatment.
- 150 4. Women with more than three embryos transferred in any treatment since this was a very
151 rare occurrence in the UK (20 over the whole study period).
- 152 5. Women whose first treatment in the database was a thawed embryo transfer since this
153 indicated previous unrecorded treatment.
- 154 6. Women who received their first treatment in 2008 and 2009 were excluded so that a
155 minimum of two years exposure time could be achieved for women commencing treatment
156 in 2007. Two years was chosen since this captured over 90% of women's total exposure to
157 treatment in the database. The years where the opt-in policy was in action (2010 to 2011)
158 were excluded since their inclusion would have led to falsely higher discontinuation rates
159 due to women opting not to disclose their treatment information in later treatments.

160 ***Baseline characteristics***

161 Baseline characteristics of women at the beginning of their first complete cycle included age (<31,
162 31-35, 36-40, and >40 years), type of infertility (categorised as single diagnosis of tubal,
163 endometriosis, anovulation, male factor, or unexplained, or as any multiple diagnosis), and year.

164 ***Outcomes***

165 Since the complete cycle information was linked to individual women, this enabled us to identify the
166 first live birth and first multiple pregnancy occurrences per woman over multiple complete cycles.
167 Once a woman achieved her first live born baby from IVF they did not contribute any further to the
168 cumulative rates. Outcomes were cumulative live birth rate per woman (CLBR), cumulative term
169 singleton live birth rate per woman, and cumulative multiple pregnancy rate per pregnant woman.

170 Multiple pregnancy was defined as an occurrence of: more than one foetal sac each with foetal
171 pulsation on scan; or one foetal sac but more than one birth outcome.

172 ***Statistical analysis***

173 Descriptive statistics were calculated for patient and treatment characteristics at the first fresh IVF
174 treatment. The median (interquartile range (IQR)) number of treatments per patient, median
175 follow-up time and the most frequent fresh and frozen-thawed treatment patterns per patient were
176 calculated. The live birth rate at the first fresh IVF treatment was calculated by year. These results
177 were used to inform the development of separate time periods over which the CLBRs were
178 calculated. This would enable investigation of the improvement in cumulative rates over time.
179 Three different live birth rates were estimated:

180 *Live birth rate and multiple pregnancy rate (per complete cycle)*

181 The live birth rate per complete cycle was calculated by dividing the number of women in each
182 complete cycle who had their first live birth by the total number of women who attempted that
183 complete cycle. The multiple pregnancy rate per complete cycle was calculated by dividing the
184 number of women in each complete cycle who had their first multiple pregnancy event by the
185 number of women who had a pregnancy in that complete cycle.

186 *Conservative CLBR*

187 This assumes that none of the women who discontinued treatment would have had a live birth. At
188 each successive complete cycle the total number of women who had their first treatment dependent
189 live birth up to and including it were divided by the total number of women who ever attempted IVF.
190 Any further live births occurring in subsequent cycles were not included in this analysis. The 95%
191 confidence intervals were calculated using standard errors from the binomial distribution.

192 *Optimal CLBR*

193 This assumes that women who discontinued treatment would have had the same chance of a live
194 birth or a multiple pregnancy as those who continued. The Kaplan-Meier estimate was used to
195 calculate these rates and pointwise estimates of the 95% confidence intervals were obtained.

196 Cumulative rates were calculated by different age group and type of infertility values. This utilised
197 the linked data by using the values of these characteristics of the woman at the start of her first
198 complete cycle. For CLBR, all complete cycles were included up to either the end of follow-up or the
199 first live birth occurrence, whichever came first.

200 The CLBR was only calculated for complete cycles where the number of women attempting that
201 complete cycle was greater than 100. The above analyses were repeated for the outcome of term
202 singleton live birth. The log-rank test was used to compare the optimal CLBRs between the two time
203 periods and between age and type of infertility within each time period. The conservative
204 cumulative multiple pregnancy rate per pregnant woman was calculated by dividing the number of
205 women in each complete cycle who had their first multiple pregnancy event by the number of
206 women who got pregnant up until that complete cycle.

207 ***Ethical approval***

208 Ethical approval was obtained by the North of Scotland Research Ethics Committee (12/NS/0119).

209

210 **Results**

211 A total of 253,417 women underwent 464,333 autologous complete cycles of IVF in the UK from
212 1992 to 2011. After exclusions these figures reduced to 218,591 women (438,454 complete cycles)
213 (see Figure 1). The live birth rate resulting from the first complete cycle of IVF increased from 16.1%
214 in 1992 to 31.2% in 2007 (see Figure S1). From 1992 to 1998 the rates slowly increased to 23.1%
215 before rising to 26.1% in 1999 where they remained steady until 2006 (29.7%). Based on the

216 stability of annual success rates for the first complete cycle, the CLBR was calculated for women who
217 commenced IVF from 1999 to 2007. This was to minimize heterogeneity caused by changes in
218 clinical practice over time. To assess whether the CLBR improved over time, the CLBR was also
219 calculated for the earlier time period of 1992 to 1998 (period 1) and compared to the CLBR for 1999
220 to 2007 (period 2). A total of 71,551 women commenced IVF during period 1 and 107,347 during
221 period 2 (see Figure 1). Table 1 shows couple and treatment characteristics at the start of the first
222 complete cycle by time period. The proportion of women over the age of 35 who received IVF
223 increased over time from 31.7% during period 1 to 39.6% during period 2. Unexplained infertility,
224 the most frequent diagnosis during period 1 (43.8%) slipped to second place during the second
225 period (27.2%) behind male factor (31.1%). In the first fresh treatment, the proportion of triple
226 embryo transfers decreased from 38.8% in period 1 to 8.4% in period 2 (Table 2). However, the
227 proportion of single embryo transfers remained the same (~8%) meaning that there were more
228 double embryo transfers in period 2 (69.4%) than in period 1 (32.9%). The median (IQR) number of
229 complete cycles was 1 (1, 2) in both time periods. The median (IQR) time from the start of the first
230 complete cycle to the last fresh or frozen-thawed treatment in the last complete cycle (excluding
231 women who only had one complete cycle with no frozen-thawed embryo transfer attempts) was
232 lower in period 2 compared to period 1 (365 (185, 701) versus 314 (165, 609) days; $p < 0.001$).

233 ***Treatment patterns***

234 The most frequent treatment patterns were the same in both periods: one fresh treatment (period 1
235 48.4% versus period 2 51.4%), two consecutive fresh treatments (21.8% versus 21.9%), three
236 consecutive fresh treatments (9.4% versus 8.5%), and one fresh treatment followed by one frozen-
237 thawed treatment (4.2% versus 4.3%).

238 ***Cumulative live birth rates***

239 The conservative (Figure 2A) and optimal (Figure 2B) CLBRs per woman after the third complete
240 cycle for patients who commenced IVF from 1992 to 1998 were 30.8% and 44.6% respectively,
241 increasing to 42.3% and 57.1% from 1999 to 2007 (see Table 3). The respective rates for term
242 singleton live birth were 17.4% and 27.6% for 1992 to 1998 and 25.6% and 38.5% for 1999 to 2007
243 (Table S1). There was a highly significant difference between optimal cumulative live birth rates
244 across the two time periods ($p < 0.001$). After eight complete cycles the optimal CLBR was 82.4% in
245 the latter time period. The conditional live birth rates per complete cycle tended to show a minimal
246 decline with each successive complete cycle.

247 For those patients who did not achieve a live birth following their fresh embryo transfer attempt in
248 their first complete cycle but who went on to have at least one frozen embryo transfer attempt, the
249 conditional cumulative live birth rate after three frozen embryo transfer attempts was 33.7% in
250 period 1 and 41.0% in period 2.

251 *Age group*

252 By age group, the CLBRs per women were higher in period 2 than period 1. After the third complete
253 cycle, for those aged < 31 at their first complete cycle the conservative CLBRs were 38.6% versus
254 52.4% in periods 1 and 2 respectively; ages 31-35 (34.6% versus 50.3%), ages 36-40 (22.1% versus
255 33.9%), ages > 40 (5.9% versus 9.8%). The corresponding optimal CLBRs were 54.1% versus 67.9%,
256 47.7% versus 64.2%, 33.3% versus 47.0% and 11.4% versus 17.3% respectively. In each time period
257 the optimal CLBRs were significantly different across the age groups ($p < 0.001$).

258 *Type of infertility*

259 The CLBRs for type of infertility were not calculated for Period 1 as the number of events in some
260 groups were too small. In Period 2, couples with a single diagnosis of male factor infertility at their
261 first complete cycle had the highest CLBR of all types at 45.8% for the conservative estimate and
262 59.8% for the optimal estimate after the third complete cycle. This was followed closely by

263 endometriosis (44.8% conservative, 57.5% optimal), unexplained infertility (42.2% conservative,
264 56.2% optimal), tubal infertility (39.5% conservative, 54.6% optimal), and anovulation (39.4%
265 conservative, 57.6% optimal). The CLBR for couples with more than one type of infertility was
266 similar to that for couples with single types of infertility (40.1% conservative, 55.5% optimal). There
267 was a significant difference between the optimal CLBRs across the types of infertility in the second
268 period ($p < 0.001$).

269 ***Multiple pregnancy rates by time period***

270 By time period, 7495 (30.9%) of 24296 pregnancies during 1992 to 1997 were multiple pregnancies
271 of which 6368 (85.0%) resulted in a multiple live birth. For IVF commencing during 1998 to 2007,
272 13702 (24.8%) of 55270 pregnancies were multiple pregnancies of which 11767 (85.9%) led to a
273 multiple live birth. The multiple pregnancy rate per pregnant woman after the first complete cycle
274 was 31.9% for those that commenced during period 1 and decreased to 26.2% during period 2.
275 Cumulatively, the multiple pregnancy rates did not increase i.e. they remained the same as the rate
276 in the first complete cycle for each period.

277 ***Discontinuation***

278 The discontinuation rates after each complete cycle were very similar for the two time periods. Of
279 those women whose first complete cycle did not result in a live birth 42.7% did not return for a
280 second complete cycle over the following two years in period 1 versus 39.5% in period 2 (Figure S2).
281 The withdrawal rate per complete cycle increased until complete cycle four and then remained
282 reasonably steady.

283

284 **Discussion**

285 ***Statement of principal findings***

286 In this study, national UK cumulative birth outcomes following one or more IVF complete cycles
287 were calculated over two separate time periods – 1992 to 1998 and 1999 to 2007. The conservative
288 estimates of the CLBR after three complete cycles increased by almost 40% from the earlier to the
289 later period (from 30.8% to 42.3%) whilst optimal estimates increased by 30% (from 44.6% to
290 57.1%). The conservative cumulative multiple pregnancy rate decreased from around 32% in period
291 1 to 26% in period 2 across all complete cycles. By age group, the CLBR per woman declined from the
292 age of 31 to 35 years. There was little difference between the CLBRs across the different types of
293 infertility with conservative estimates ranging from 39% to 46% from 1999 to 2007. The log-rank
294 test was statistically significant for this difference, however, this is almost certainly due to the large
295 population size.

296 ***Strengths and weaknesses of the study***

297 This is the first study to report CLBRs per woman following autologous IVF treatment for the whole
298 of the UK using national population-based data from 1992 to 2009. Per woman rates were
299 estimable because all IVF treatments were linked to the woman, a unique strength for a national IVF
300 database with a long history of complete treatment capture. CLBRs were calculated over complete
301 IVF cycles including fresh and frozen-thawed embryo transfers. This makes the results much more
302 relevant for clinicians and patients.

303 Although we were able to link all treatments within women, it was not possible to identify with
304 certainty from which complete cycle (i.e. episode of ovarian stimulation) each replaced frozen-
305 thawed embryo came. However, our assumption that any frozen-thawed embryos were most likely
306 to have been derived from the most recent egg retrieval episode is likely to be correct for all but a
307 minority of women who may have undergone multiple consecutive fresh transfer attempts and
308 reserved all frozen embryos for transfer at a later date. In reality, only 14% of all women in our
309 dataset had a frozen-thawed embryo transfer attempt; thus, CLBRs tended to be dominated by the
310 outcome of the first fresh treatment. CLBRs could not be calculated for women who started

311 treatment in 2008-2009 since the minimum two-year treatment exposure time would have
312 overlapped the phase, which began in October 2009, when patients had to give formal consent for
313 their data to be disclosed for research purposes (Human Fertilisation and Embryology Authority
314 2008b).

315 ***Strengths and weaknesses in relation to other studies***

316 The conservative estimate of the CLBR is a pessimistic one since it assumes that women who do not
317 achieve a live birth do not have any continued chance of getting pregnant – it reflects the observed
318 treatment specific CLBR. The optimal estimate is seen as optimistic since it assumes that women
319 who discontinue without having a live birth still have the same chance of a live birth as those who
320 continue. This future chance of live birth can be interpreted as either a hypothetical ideal world
321 scenario where there is no barrier to future treatment (which is only true for some women) or as
322 one arising from a natural conception (assuming that such chances are similar to those who continue
323 with IVF). A 'realistic' estimate of the CLBR can be calculated which assumes that women who
324 discontinue because of a medical indication had no continued chance of achieving a live birth, while
325 those who stopped treatment for other reasons had the same probability of achieving a live birth
326 after IVF as those who continued (Stolwijk et al. 2000). Unfortunately the HFEA database did not
327 hold the reasons for discontinuation of IVF treatment meaning calculation of the realistic estimate
328 was not possible. However, a previous study found that 22.5% of women who failed 2-4 IVF
329 attempts went on to have a treatment dependent live birth (Troude et al. 2012). Assuming a similar
330 rate in our study gives a realistic estimate of approximately 55.3% after three complete cycles which
331 is just lower than the optimal estimate of 57.1%. Without knowing the reason for withdrawal it is
332 possible that the realistic estimate may show lower rates for the later time period compared to the
333 earlier time period. For this to happen it would mean that the discontinuation rate due specifically
334 to medical indication had increased sufficiently enough over time to have the effect of lowering the

335 CLBR. With the lowering of the threshold for IVF treatment this is unlikely to be the case (Kamphuis
336 et al. 2014).

337 It is not possible to directly compare the finding from the current study with that from the US since
338 the latter did not assess the CLBRs over complete cycles of IVF but did so over cumulative fresh or
339 frozen-thawed treatments (Luke et al. 2012). Also, the US study period was 2004 to 2008 whilst the
340 present study's latter time period was from 1999 to 2007.

341 In Australia and New Zealand, the overall conservative CLBR after three successive fresh or frozen-
342 thawed embryo transfers was 36.0% which is slightly lower than the UK rate of 39.8% after three
343 complete cycles (Macaldowie et al. 2013). However, as for the US, that study examined CLBRs over
344 cumulative fresh or frozen-thawed treatments rather than complete cycles as in our study. The
345 study period was 2009 to 2011 meaning that only those women who began treatment in 2009
346 contributed at least two years' worth of treatment to the cumulative rates.

347 ***Meaning of the study***

348 Our results provide an estimate of the chances of a couple taking a baby home after one or more
349 complete cycles of IVF. They also confirm the fact that, despite rising female age, the CLBR in the
350 U.K. has increased over time while the multiple pregnancy rate has declined. This reflects
351 improvements in reproductive technology and the evolution towards a more conservative embryo
352 transfer policy (McLernon et al. 2010). The multiple pregnancy rate per pregnant woman reduced
353 from 31.9% in women who commenced IVF during period 1 to 26.2% during period 2 reflecting the
354 reduction in triple embryo transfers. The latter rate is slightly lower than that reported in Canada in
355 2004 of 30% (Health Quality Ontario, 2006) and is actually lower than many countries' multiple birth
356 rate including Guatemala (71.5%), Brazil (55.9%), Argentina (43.1%), Taiwan (40.5%) and USA
357 (31.5%) (Sullivan et al. 2013). Since the end of our study period the HFEA have reported that the
358 multiple pregnancy rate has reduced further to 16.4% in 2013 (Human Fertilisation and Embryology

359 Authority 2015) reflecting the strong drive by the HFEA to reduce the multiple pregnancy rate
360 (Human Fertilisation and Embryology Authority 2013c).

361

362 Elective single embryo transfer (SET) with cryopreservation of surplus embryos can optimise the
363 safety and success of IVF (National Collaborating Centre for Women's and Children's Health 2013).
364 The traditional focus on presenting outcomes per fresh IVF treatment has tended to discourage use
365 of elective SET which, inevitably, is associated with slightly lower live birth rates per fresh treatment
366 but comparable cumulative outcomes. In addition, given the relatively modest success rates of IVF
367 per fresh/frozen-thawed embryo transfer, commissioners and health planners, as well as patients
368 who pay for IVF appreciate being able to base their decisions regarding treatment on a realistic
369 expectation of CLBRs after one or more complete cycles of IVF i.e. a package of fresh (and their
370 accompanying frozen-thawed) treatments.

371 Despite NICE recommendations in 2004, most couples in the UK still do not receive three complete
372 IVF cycles. The majority of patients discontinue IVF after receiving one complete cycle which may be
373 due to various reasons including the National Health Service's rationing of IVF in different regions
374 (National Institute for Health and Clinical Excellence 2014), a lack of personal funds, psychological
375 burden of treatment, relationship problems/divorce, physical burden (Lande et al. 2014, Verberg et
376 al. 2008, Olivius et al. 2004). This was reflected in the conservative CLBRs which stabilised after three
377 successive complete cycles. For those women with no barrier to continued treatment, our results
378 show that the CLBR after eight complete cycles would be 82% (optimal estimate) which is similar to
379 the live birth rate within two years in 30 to 35 year old women from a simulated natural population
380 (Leridon 2004). The per complete cycle live birth rates declined slowly with each successive
381 complete cycle e.g. a woman starting her second complete cycle of treatment has almost as high a
382 chance of success as when she started her first. Our findings offer important reassurance to women
383 contemplating whether to persist with treatment. They also add further support to a recent call

384 from NICE to end the postcode lottery of IVF treatment and to develop consistent IVF policies on
385 access to treatment across all clinical commissioning groups (Everywomen 2013). Our findings for
386 the optimal CLBR should be reassuring for countries, such as Belgium (Berg Brigham et al. 2013) and
387 Israel (Lande et al. 2011), who conduct more than the UK's maximum of three complete cycles and
388 where lack of patient funds is not such a potential barrier to treatment.

389 ***Unanswered questions and future research***

390 CLBRs per woman over time are useful to inform clinicians, patients and policy makers about the
391 national improvement in success rates and the overall chances of live birth. However, there is a
392 need to provide patients with a more individualised estimate of their chances of live birth over
393 multiple complete cycles. Clinical prediction models would allow clinicians to make more informed
394 treatment decisions tailored to the characteristics of the woman and her treatment. The recently
395 released IVFPredict clinical prediction tool can estimate the probability of a live birth for a specific
396 treatment attempt number (Nelson and Lawlor 2011). However, it cannot estimate the cumulative
397 chances of a live birth over multiple complete cycles of IVF.

398 ***Conclusions***

399 The last two decades have witnessed a rise in CLBRs accompanied by a decline in multiples. Yet
400 most UK couples who do not conceive after their first complete cycle do not receive a further two
401 complete NHS funded IVF cycles as recommended by NICE. If there were no barriers to continuation
402 of IVF treatment, around 83% of women receiving IVF would achieve a live birth by the eighth
403 complete cycle, similar to the natural live birth rate in a non-contraception practising population.
404 These data should be used to inform policy and counsel patients commencing IVF treatment.

405

406 **Acknowledgements**

407 We thank the Human Fertilisation and Embryological Authority (HFEA) for granting us permission to
408 analyse their database, for extracting the requested information, and for assisting with our queries
409 in an efficient manner.

410 We acknowledge the data management support of the Grampian Data Safe Haven (DaSH) and the
411 associated financial support of NHS Research Scotland, through NHS Grampian investment in the
412 Grampian DaSH. For more information, visit the DaSH website
413 <http://www.abdn.ac.uk/iahs/facilities/grampian-data-safe-haven.php>.

414 **Author's Roles**

415 DJM, SB, AM and AJL designed the study. DJM conducted the statistical analysis, literature search,
416 and wrote the article. All authors contributed intellectually to the writing or revising of the
417 manuscript, and approved the final version. DJM is the guarantor.

418 **Funding**

419 This work was supported by a Chief Scientist Office Postdoctoral Training Fellowship in Health
420 Services Research and Health of the Public Research (Ref PDF/12/06). The views expressed here are
421 those of the authors and not necessarily those of the Chief Scientist Office. The funder did not have
422 any role in the study design; in the collection, analysis, and interpretation of data; in the writing of
423 the report; nor in the decision to submit the paper for publication. DM had full access to all the data
424 in the study and had final responsibility for the decision to submit for publication.

425 **Competing interests:** All authors have completed the ICMJE uniform disclosure form at
426 www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author). SB reports
427 grants from Chief Scientist Office Scotland during the conduct of the study. His institution has
428 received support from Pharmaceutical companies (for educational seminars) which is not related to
429 the submitted work. DJM, AM and AJL have no conflicts of interest to declare.

430

431 **References**

- 432 Abuzeid MI, Bolonduro O, La Chance J, Abozaid T, Urich M, Ullah K, Ali T, Ashraf M, Khan I.
433 Cumulative live birth rate and assisted reproduction: impact of female age and transfer day. *Facts*
434 *Views Vis Obgyn* 2014; **6**: 145-149.
- 435 Adamson GD, Zegers-Hochschild F, Ishihara O, Sullivan E, Mansour R, Nygren KG, Banker M, Dyer S,
436 de Mouzon J. ICMART world report: preliminary 2008 data. *Hum Reprod* 2012; **27**: Suppl 2:ii38-ii39.
- 437 Berg Brigham K, Cadier B, Chevreul K. The diversity of regulation and public financing of IVF in
438 Europe and its impact on utilization. *Hum Reprod* 2013; **28**: 666-675.
- 439 Bhattacharya S, Maheshwari A, Mollison. Factors associated with failed treatment: an analysis of
440 121,744 women embarking on their first IVF cycles. *PLOS One* 2013; **8**: e82249.
- 441 Boivin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and
442 treatment-seeking: potential need and demand for infertility medical care. *Hum Reprod* 2007; **22**:
443 1506-1512.
- 444 De Mouzon J, Goossens V, Bhattacharya S, Castilla JA, Ferraretti AP, Korsak V, Kupka M, Nygren KG,
445 Nyboe Andersen A, European IVF-monitoring (EIM) Consortium, for the European Society of Human
446 Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2006: results
447 generated from European registers by ESHRE. *Hum Reprod* 2010; **25**: 1851–1862.
- 448 Elizur SE, Lerner-Geva L, Levron J, Shulman A, Bider D, Dor J. Cumulative live birth rate following in
449 vitro fertilization: study of 5310 cycles. *Gynecol Endocrinol* 2006; **22**: 25-30.
- 450 Everywomen J. Cassandra’s prophecy: why we need to tell the women of the future about age-
451 related fertility decline and ‘delayed’ childbearing. *Reprod BioMed Online* 2013; **27**: 4-10.

452 Health Quality Ontario. In vitro fertilization and multiple pregnancies: an evidence-based analysis.
453 *Ont Health Technol Assess Ser.* 2006; **6**: 1–63.

454 Human Fertilisation and Embryology Authority. A long term analysis of the HFEA register data (1991–
455 2006). 2008a. [http://www.hfea.gov.uk/docs/Latest_long_term_data_analysis_report_91-
456 06.pdf\(1\).pdf](http://www.hfea.gov.uk/docs/Latest_long_term_data_analysis_report_91-06.pdf(1).pdf).

457 HFEA's Human Fertilisation and Embryology Act 2008b
458 <http://www.legislation.gov.uk/ukpga/2008/22/contents#pt1-pb8-l1g25>.

459 Human Fertilisation and Embryology Authority. Fertility treatment in 2012: trends and figures. 2012.
460 <http://www.hfea.gov.uk/docs/FertilityTreatment2012TrendsFigures.PDF>.

461 Human Fertilisation and Embryology Authority. Fertility treatment in 2013: trends and figures.
462 2013a. http://www.hfea.gov.uk/docs/HFEA_Fertility_Trends_and_Figures_2013.pdf.

463 Human Fertilisation and Embryology Authority. Access anonymised HFEA data. 2013b.
464 <http://www.hfea.gov.uk/5874.html>.

465 Human Fertilisation and Embryology Authority. Multiple births and single embryo transfer review.
466 2013c. <http://www.hfea.gov.uk/Multiple-births-after-IVF.html>.

467 Human Fertilisation and Embryology Authority. Facts & figures for researchers and the media. 2014.
468 <http://www.hfea.gov.uk/99.html>.

469 Human Fertilisation and Embryology Authority. Improving outcomes for fertility patients: multiple
470 births. 2015. http://www.hfea.gov.uk/docs/Multiple_Births_Report_2015.pdf.

471 Johnson MH, Franklin S. Editorial: A patient perspective. *Reprod BioMed Online* 2013; **27**: 1-3.

472 Jones Jr HW, Jones D, Kolm P. Cryopreservation: a simplified method of evaluation. *Hum Reprod*
473 1997; **12**: 548-553.

474 Kamphuis EI, Bhattacharya S, van der Veen F, Mol BWJ, Templeton. A Are we overusing IVF? *Br Med*
475 *J* 2014; **348**: g252

476 Ke H, Chen X, Liu Y, Ye D, He Y, Chen A. Cumulative live birth rate after three ovarian stimulation IVF
477 cycles for poor ovarian responders according to the Bologna criteria. *J Huazhong Univ Sci Technol*
478 2013; **33**: 418-422.

479 Lande Y, Seidman DS, Maman E, Baum M, Dor J, Hourvitz A. Couples offered free assisted
480 reproduction treatment have a very high chance of achieving a live birth within 4 years. *Fertil Steril*
481 2011; **95**: 568-572.

482 Lande Y, Seidman DS, Maman E, Baum M, Hourvitz A. Why do couples discontinue unlimited free IVF
483 treatments? *Gynecol Endocrinol* 2014; doi: 10.3109/09513590.2014.982082.

484 Leridon H. Can assisted reproduction technology compensate for the natural decline in fertility with
485 age? A model assessment. *Hum Reprod* 2004; **19**: 1548-1553.

486 Luke B, Brown MB, Wantman E, et al. Cumulative birth rates with linked assisted reproductive
487 technology cycles. *N Engl J Med* 2012; **366**: 2483-2491.

488 Macalldowie A, Wang YA, Chambers GM, Sullivan EA. Assisted reproduction technology in Australia
489 and New Zealand 2011. 2013. National Perinatal Epidemiology and Statistics Unit, the University of
490 New South Wales, Sydney. [https://npesu.unsw.edu.au/surveillance/assisted-reproductive-](https://npesu.unsw.edu.au/surveillance/assisted-reproductive-technology-australia-new-zealand-2011)
491 [technology-australia-new-zealand-2011](https://npesu.unsw.edu.au/surveillance/assisted-reproductive-technology-australia-new-zealand-2011).

492 Maheshwari A, McLernon D, Bhattacharya S. Cumulative live birth rate: time for a consensus? *Hum*
493 *Reprod* 2015; doi:10.1093/humrep/dev263.

494 Malizia BA, Hacker MR, Penzias AS. Cumulative live-birth rates after in vitro fertilization. *N Engl J*
495 *Med* 2009; **360**: 236-243.

496 Mansour R, Ishihara O, Adamson GD, Dyer S, de Mouzon J, Nygren KG, Sullivan E, Zegers-Hochschild
497 F. International Committee for Monitoring Assisted Reproductive Technologies world report:
498 Assisted Reproductive Technology 2006. *Hum Reprod* 2014; **29**: 1536-1551.

499 McLernon DJ, Harrild K, Bergh C, Davies MJ, de Neubourg D, Dumoulin JCM, Gerris J, Kremer JAM,
500 Martikainen H, Mol BW, et al. Clinical effectiveness of elective single versus double embryo transfer:
501 meta-analysis of individual patient data from randomised trials. *BMJ* 2010; **341**: c6945.

502 Min JK, Breheny SA, MacLachlan V, Healy DL. What is the most relevant standard of success in
503 assisted reproduction? The singleton, term gestation, live birth rate per cycle initiated: the BESST
504 endpoint for assisted reproduction. *Hum Reprod* 2004; **19**: 3-7.

505 Moragianni VA, Penzias AS. Cumulative live-birth rates after assisted reproductive technology. *Curr*
506 *Opin Obstet Gynecol* 2010; **22**: 189-192.

507 National Collaborating Centre for Women's and Children's Health. Fertility: assessment and
508 treatment for people with fertility problems. National Institute for Health and Clinical Excellence
509 clinical guideline. 2013. [http://www.nice.org.uk/guidance/cg156/evidence/cg156-fertility-full-](http://www.nice.org.uk/guidance/cg156/evidence/cg156-fertility-full-guideline3)
510 [guideline3](http://www.nice.org.uk/guidance/cg156/evidence/cg156-fertility-full-guideline3).

511 National Institute for Health and Clinical Excellence. NICE calls for an end to postcode lottery of IVF
512 treatment. 2014. [https://www.nice.org.uk/news/article/nice-calls-for-an-end-to-postcode-lottery-](https://www.nice.org.uk/news/article/nice-calls-for-an-end-to-postcode-lottery-of-ivf-treatment)
513 [of-ivf-treatment](https://www.nice.org.uk/news/article/nice-calls-for-an-end-to-postcode-lottery-of-ivf-treatment).

514 Nelson SM, Lawlor DA. Predicting live birth, preterm delivery, and low birth weight in infants born
515 from in vitro fertilisation: a prospective study of 144,018 treatment cycles. *PLOS Med* 2011; **8**:
516 e1000386.

517 Oakley L, Doyle P, Maconochie N. Lifetime prevalence of infertility and infertility treatment in the
518 UK: results from a population-based survey of reproduction. *Hum Reprod* 2008; **23**: 447-450.

519 Olivius C, Friden B, Borg G, Bergh C. Why do couples discontinue in vitro fertilization treatment? A
520 cohort study. *Fertil Steril* 2004; **81**: 258-261.

521 Roque M, Lattes K, Serra S, Solà I, Geber S, Carreras R, Checa MA. Fresh embryo transfer versus
522 frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis. *Fertil*
523 *Steril* 2013; **99**: 156–162.

524 Sharma V, Allgar V, Rajkhowa, M. Factors influencing the cumulative conception rate and
525 discontinuation of in vitro fertilization treatment for infertility. *Fertil Steril* 2002; **78**: 40-46.

526 Stern JE, Hickman TN, Kinzer D, Penzias AS, Ball GD, Gibbons WE. Can the Society for Assisted
527 Reproductive Technology Clinic Outcome Reporting System (SART CORS) be used to accurately
528 report clinic total reproductive potential (TRP)? *Fertil Steril* 2012; **97**: 886-889.

529 Stern JE, Brown MB, Wantman E, Kalra SK, Luke B. Live birth rates and birth outcomes by diagnosis
530 using linked cycles from the SART CORS database. *J Assist Reprod Genet* 2013; **30**: 1445-1450.

531 Stolwijk AM, Wetzels AMM, Braat DDM. Cumulative probability of achieving an ongoing pregnancy
532 after in-vitro fertilization and intracytoplasmic sperm injection according to a woman's age,
533 subfertility diagnosis and primary or secondary subfertility. *Hum Reprod* 2000; **15**: 203-209.

534 Sullivan EA, Zegers-Hochschild F, Mansour R, Ishihara O, de Mouzon J, Nygren KG, Adamson GD.
535 International Committee for Monitoring Assisted Reproductive Technologies (ICMART) world report:
536 assisted reproductive technology 2004. *Hum Reprod* 2013; **28**: 1375-1390.

537 Sunderam SKD, Kissin DM, Crawford SB, Folger SG, Jamieson DJ, Barfield WD. Assisted Reproductive
538 Technology Surveillance – United States, 2011. *MMWR Surveill Summ* 2014; **63**: 1–28.

539 Sunkara SK, Rittenberg V, Raine-fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association
540 between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles.
541 *Hum Reprod* 2011; **26**: 1768-1774.

542 The Multiple Births Foundation. One at a time. <http://www.oneatatime.org.uk>.

543 Troude P, Bailly E, Guibert J, Bouyer J, de la Rochebrochard E, for the DAIFI Group. Spontaneous
544 pregnancies among couples previously treated by in vitro fertilization. *Fertil Steril* 2012; **98**: 63-
545 68. Verberg MFG, Eijkemans MJC, Heijnen EMEW, Broekmans FJ, de Klerk C, Fauser BCJM, Macklon
546 NS. Why do couples drop-out from IVF treatment? A prospective cohort study. *Hum Reprod* 2008;
547 **23**: 2050-2055.

548 Vrtacnik U, Bokal EV, Davjak R. Cumulative delivery rate after providing full reimbursement in vitro
549 fertilization programme: a 6-years survey. *BioMed Res Int* 2014;
550 <http://dx.doi.org/10.1155/2014/850478>.

551 Williams CL, Bunch KJ, Stiller CA, Murphy MFG, Botting BJ, Wallace WH, Davies M, Sutcliffe AG.
552 Cancer risk among children born after assisted conception. *New Engl J Med* 2013; **369**: 1819-1827.

553

554

555

556

557

558

559

560

561

562

563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580

Table 1. Characteristics of the couple at the start of their first complete cycle

Characteristics	Period, N(%), unless otherwise stated	
	1992 to 1998 N=71551	1999 to 2007 N=107347
Female Age (y), mean (SD)	33.4 (4.5)	34.1 (4.6)
<31	19646 (27.5)	23391 (21.8)
31 to 35	29260 (40.9)	41459 (38.6)
36 to 40	18343 (25.6)	33866 (31.5)
>40	4302 (6.0)	8631 (8.0)
Duration (y), median (IQR)	2 (2 to 4)	4 (3 to 6)
Type of infertility		
Unexplained only	31353 (43.8)	29181 (27.2)
Tubal only	10716 (15.0)	17634 (16.4)
Anovulation only	1115 (1.6)	7425 (6.9)
Endometriosis only	965 (1.3)	3591 (3.3)
Cervical only	83 (0.1)	47 (0.0)
Male factor only	440 (0.6)	33427 (31.1)
>1 type of infertility	26879 (37.6)	16042 (14.9)

581
582

Table 2. Treatment information for women commencing IVF during two time periods

Treatment information	Period, N(%), unless otherwise stated	
	1992 to 1998 N=71551	1999 to 2007 N=107347
<i>First fresh treatment characteristics</i>		
IVF	59322 (82.9)	64587 (60.2)
ICSI	12229 (17.1)	42760 (39.8)
Number of oocytes, median (IQR)	8 (4, 12)	8 (5, 13)
Number of embryos created, median (IQR)	4 (1, 7)	5 (2, 8)
Number of embryos transferred		
0	14349 (20.1)	14831 (13.8)
1	5886 (8.2)	9038 (8.4)
2	23555 (32.9)	74496 (69.4)
3	27761 (38.8)	8982 (8.4)
Cryopreservation of embryos	15184 (21.2)	27711 (25.8)
<i>Overall treatment information (per woman)</i>		
Number of fresh/frozen treatment attempts until end of follow-up ¹ , median (IQR)	2 (1, 3)	1 (1, 2)
Number of complete cycles until end of follow-up ¹ , median (IQR)	1 (1, 2)	1 (1, 2)
Number of couples with at least one frozen embryo transfer attempt	10609 (14.8%)	14979 (14.0%)
Number of complete cycles until first live birth ² , median (IQR)	1 (1, 2)	1 (1, 2)
Time (days) from first fresh treatment attempt to last fresh/frozen treatment attempt, median (IQR) ³	365 (185, 701)	314 (165, 609)
Time (days) from first fresh treatment attempt to last fresh/frozen treatment attempt leading to live birth ² , median (IQR)	0 (0, 282)	0 (0, 196)

583

584 ¹ Follow-up defined as first live birth or end of study (whichever came first)

585 ² Only includes women who had a live birth

586 ³ Excludes women who only had one fresh treatment attempt i.e. no frozen embryo transfer
587 attempts or further ovarian stimulations.

588
589

Table 3. Live birth rates per complete cycle and cumulative live birth rates per woman by period


Period	Complete cycle	No. Women	No. women with at least one live birth	Conditional live birth rate	Conservative cumulative live birth rate	Optimal cumulative live birth rate
1992-1998	1	71551	13697	19.1 (18.85, 19.43)	19.1 (18.85, 19.43)	19.1 (18.86, 19.43)
	2	33155	5960	18.0 (17.56, 18.39)	27.5 (27.15, 27.80)	33.7 (33.27, 34.09)
	3	14288	2356	16.5 (15.88, 17.10)	30.8 (30.43, 31.10)	44.6 (44.09, 45.145)
	4	5649	905	16.0 (15.06, 16.98)	32.0 (31.69, 32.37)	53.5 (52.80, 54.18)
	5	2135	333	15.6 (14.06, 17.14)	32.5 (32.15, 32.84)	60.7 (59.82, 61.67)
	6	878	117	13.3 (11.08, 15.57)	32.7 (32.32, 33.00)	66.0 (64.78, 67.16)
	7	372	51	13.7 (10.21, 17.20)	32.7 (32.39, 33.07)	70.6 (69.06, 72.20)
	8	147	14	9.5 (4.78, 14.27)	32.8 (32.41, 33.09)	73.4 (71.43, 75.41)
1999-2007	1	107347	30546	28.5 (28.19, 28.73)	28.5 (28.19, 28.73)	28.5 (28.19, 28.73)
	2	46439	11116	23.9 (23.55, 24.32)	38.8 (38.52, 39.10)	45.6 (45.24, 45.93)
	3	17913	3791	21.2 (20.57, 21.76)	42.3 (42.05, 42.64)	57.1 (56.67, 57.52)
	4	6253	1189	19.0 (18.04, 19.99)	43.5 (43.15, 43.75)	65.3 (64.71, 65.80)
	5	2175	365	16.8 (15.21, 18.35)	43.8 (43.49, 44.09)	71.1 (70.38, 71.79)
	6	793	121	15.3 (12.76, 17.76)	43.9 (43.61, 44.20)	75.5 (74.55, 76.43)
	7	292	44	15.1 (10.97, 19.17)	43.9 (43.65, 44.24)	79.2 (77.89, 80.46)
	8	110	17	15.5 (8.70, 22.21)	44.0 (43.66, 44.26)	82.4 (80.59, 84.14)

590


591

592

Figure 1 Flow chart of exclusion criteria



595 **Figure 2:** (A) Conservative cumulative live birth rates per woman and (B) optimal cumulative live
596 birth rates per woman over multiple complete cycles of IVF (including ICSI) for women commencing
597 treatment in 1992 to 1998 or 1999 to 2007



598

599

600

601

602

603 **Web extra material**

604

605 **Cumulative live birth rates per woman following in vitro fertilisation: a population-**
606 **based study of data from 178,898 women**

607

608 **Contents**

609

610 Table S1 Term singleton live birth rates per complete cycle and cumulative term singleton live birth rates per
611 woman by period

612

613 Figure S1 Conditional live birth rate after the first complete cycle of IVF (including ICSI) by year

614 Figure S2 Discontinuation rate by complete cycle number by time period of first IVF treatment (including

615 ICSI)

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641


Table S1 Term singleton live birth rates per complete cycle and cumulative term singleton live birth rates per woman by period

Period	Complete cycle	No. Women	No. women with at least one term singleton live birth	Conditional term singleton live birth rate	Conservative cumulative term singleton live birth rate	Optimal cumulative term singleton live birth rate
1992-1998	1	71551	7596	10.6 (10.39, 10.84)	10.6 (10.39, 10.84)	10.6 (10.39, 10.84)
	2	33675	3451	10.2 (9.92, 10.57)	15.4 (15.17, 15.70)	19.8 (19.43, 20.13)
	3	14642	1430	9.8 (9.29, 10.25)	17.4 (17.16, 17.72)	27.6 (27.11, 28.12)
	4	5833	553	9.5 (8.73, 10.23)	18.2 (17.93, 18.49)	34.5 (33.77, 35.19)
	5	2218	217	9.8 (8.55, 11.02)	18.5 (18.23, 18.80)	40.9 (39.86, 41.92)
	6	923	75	8.1 (6.36, 9.89)	18.6 (18.33, 18.90)	45.7 (44.29, 47.11)
	7	397	29	7.3 (4.75, 9.86)	18.7 (18.37, 18.94)	49.7 (47.77, 51.58)
	8	159	12	7.5 (3.44, 11.65)	18.7 (18.39, 18.96)	53.5 (50.76, 56.19)
1999-2007	1	107347	18058	16.8 (16.60, 17.05)	16.8 (16.60, 17.05)	16.8 (16.60, 17.05)
	2	47505	6973	14.7 (14.36, 15.00)	23.3 (23.06, 23.57)	29.0 (28.71, 29.36)
	3	18600	2491	13.4 (12.90, 13.88)	25.6 (25.38, 25.90)	38.5 (38.09, 38.99)
	4	6583	778	11.8 (11.04, 12.60)	26.4 (26.10, 26.63)	45.8 (45.18, 46.42)
	5	2337	243	10.4 (9.16, 11.64)	26.6 (26.33, 26.85)	51.4 (50.57, 52.31)
	6	870	89	10.2 (8.22, 12.24)	26.7 (26.41, 26.94)	56.4 (55.16, 57.66)
	7	318	36	11.3 (7.84, 14.80)	26.7 (26.44, 26.97)	61.3 (59.46, 63.22)
	8	121	12	9.9 (4.59, 15.24)	26.7 (26.45, 26.98)	65.2 (62.50, 67.83)

1

2 **Figure S1 Conditional live birth rate after the first complete cycle of IVF (including ICSI) by year**

3



4

5

6

7

8

9

10

11

12

13

14


15

16

17

18

19 **Figure S2 Discontinuation rate by complete cycle number by time period of first IVF treatment**
20 **(including ICSI)**
21



22

23

24

25

26